Cohance Lifesciences Proposes $18 Million Investments In NJ Bio And Aruka Bio

Cohance proposed investing USD 13 million to raise NJ Bio ownership from 56.0% to 67.3%, alongside a USD 5 million controlling investment in preclinical ADC developer Aruka Bio. Aruka will become a direct subsidiary, with transactions funded through internal accruals and expected to close by end-September 2026.